Items Tagged ‘Indolent/Low Grade Non-Hodgkin’s Lymphoma’

February 24th, 2015

FDA Approves New Indication for Ibrutinib in Waldenström’s Macroglobulinemia

By

The US Food and Drug Administration (FDA) today expanded the approved use of Imbruvica® (ibrutinib) for patients with Waldenström’s macroglobulinemia, a rare type of B-cell lymphoma. Imbruvica® is the first therapy indicated specifically for Waldenström’s macroglobulinemia and previously received Breakthrough Therapy designation for this use. A type of non-Hodgkin lymphoma, Waldenström’s macroglobulinemia usually gets worse […]

View full entry

Tags: b-cell lymphoma, Breakthrough Therapy, ibrutinib, imbruvica, Indolent/Low Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Waldenström’s macroglobulinemia


December 17th, 2014

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment

By

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft function due to their need for HIV medications. Results from the clinical trial, presented at the American Society of Hematology […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Follicular Lymphoma, General HIV Related Cancers, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, hiv, hiv cancer, HIV Related Cancers, Indolent/Low Grade Non-Hodgkin's Lymphoma, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, nhl


July 21st, 2014

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment

By

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood cells from a patient and modifying them before infusion back into the patient, is currently involved in a phase […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, cd19, Chronic Lymphocytic Leukemia, CLL, Indolent/Low Grade Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, News, Non-Hodgkin's Lymphoma


September 4th, 2013

Celiac Disease Associated with Higher Risk of Lymphoma

By

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease is an autoimmune disorder of the small intestine characterized by intolerance to gluten, which is a […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Follicular Lymphoma, Health and Wellness, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, Screening/Prevention Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


February 8th, 2013

Fractionated Zevalin Effective First-Line Treatment for Advanced Follicular Lymphoma

By

Fractionated radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is an effective first-line treatment for advanced stage follicular lymphoma and delivers high response rates in patients with high tumor burden, according to the results of a phase II study presented at the 53rd annual meeting of the American Society of Hematology (ASH) in San Diego, California. Zevalin is […]

View full entry

Tags: Follicular Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


February 1st, 2013

Zevalin Effective as First-Line Treatment for Advanced Follicular Lymphoma

By

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and well tolerated and induces a high rate of clinical and molecular responses when given as first-line treatment to patients with advanced stage follicular lymphoma, according to the results of a study presented at the 52nd annual meeting of the American Society of Hematology (ASH) in Orlando, Florida. […]

View full entry

Tags: Follicular Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


January 24th, 2013

Zevalin Effective in Follicular NHL Refractory to Rituximab

By

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is effective in patients with non-Hodgkin’s lymphoma that is refractory to treatment with Rituxan® (rituximab), according to the results of a study published in the Journal of Clinical Oncology. Understanding Zevalin and RIT Zevalin therapy combines the monoclonal antibody Rituxan with Zevalin, which is comprised of an anti-CD20 monoclonal antibody […]

View full entry

Tags: Follicular Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Lymphoma, News, Non-Hodgkin's Lymphoma


January 10th, 2013

Consolidation with Zevalin Significantly Improves Progression-Free Survival in Advanced Follicular Lymphoma

By

Consolidation therapy with Zevalin® (ibritumomab tiuxetan) significantly prolongs progression-free survival and leads to high conversion rates from partial response to complete response in patients with advanced follicular lymphoma, according to the results of a study published in the Journal of Clinical Oncology. Understanding Zevalin and RIT Zevalin therapy combines the monoclonal antibody Rituxan® (rituximab) with Zevalin, […]

View full entry

Tags: Follicular Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


September 4th, 2012

Several Effective Treatment Options for Early Follicular Lymphoma

By

The results of a recent study published in the Journal of Clinical Oncology challenge the standard treatment approach for follicular lymphoma—indicating that with proper staging at diagnosis, there are several treatment regimens that can bring a remission. Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. The lymph system […]

View full entry

Tags: Indolent/Low Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


June 12th, 2012

Treanda More Effective than Standard R-CHOP for Non-Hodgkin’s Lymphoma

By

The combination of Treanda® (bendamustine) and Rituxan® (rituximab) more than doubled progression-free survival compared with standard R-CHOP therapy among patients with indolent lymphoma and mantle cell lymphoma, according to the results of a multi-center, phase III study presented at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois.[1] Non-Hodgkin’s […]

View full entry

Tags: Indolent/Low Grade Non-Hodgkin's Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


March 14th, 2012

Lymphoma During Pregnancy Can Have Good Outcomes

By

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment until after delivery. These results were presented at the 2011 annual meeting […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Early Stage Hodgkin's Lymphoma, Follicular Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


February 10th, 2012

Two Different Approaches to Rituxan Both Effective For Follicular Lymphoma

By

Among patients with low-tumor-burden follicular lymphoma who have received initial treatment with Rituxan® (rituximab), waiting until disease progression to take additional Rituxan is as effective as ongoing, maintenance Rituxan. These results were presented at the 53rd Annual meeting of the American Society of Hematology. Follicular lymphoma is an indolent (slow-growing) type of non-Hodgkin’s lymphoma. It […]

View full entry

Tags: Indolent/Low Grade Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma


May 23rd, 2011

Many Patients with “Chemo Brain” Recover within Five Years

By

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist for more than five years after treatment. These findings were recently reported in the Journal of Clinical Oncology. Chemo brain refers […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Adult Acute Lymphoblastic Leukemia, Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Allogeneic Stem Cell Transplant, Childhood Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Early Stage Hodgkin's Lymphoma


February 10th, 2011

Rituxan Approved as Maintenance Therapy for Follicular Lymphoma

By

The U.S. Food and Drug Administration (FDA) has expanded the approval of Rituxan® (rituximab) to include maintenance therapy for patients with advanced follicular lymphoma that has responded to initial treatment with Rituxan and chemotherapy. Follicular lymphoma is an indolent (slow-growing) type of non-Hodgkin’s lymphoma. It involves a type of white blood cell known as a […]

View full entry

Tags: Indolent/Low Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


March 15th, 2010

Children and Teens Have Better NHL Survival than Young Adults

By

Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in the Archives of Pediatrics and Adolescent Medicine. Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma